Vitrolife : 4 juni 2024, Handelsbanken Nordic Small & Mid Cap Seminar 2024 in Stockholm

Handelsbanken

Nordic Small & Mid Cap Seminar 2024

Bronwyn Brophy, CEO

Significant market opportunity in reproductive health

1 in 6	134 M
people globally is	babies born annually**
affected by infertility*	< 1% via IVF

Successful treatment outcomes ~33% ***

Access and

affordability constraining growth

5-7%

estimated cycle

growth in coming years

2*Source: World Health Organization **Source: United Nations ***ESHRE European mean pregnancy rate in 2019

Improvement in treatment outcomes is needed

Less than half of all embryos transferred today result in pregnancy

IVF birth rates have risen for patients under 43 in the last 30 years

Birth rates per embryo transferred using patient eggs by age band, 1991-2018, 2019 data

35%

30%

transferred	25%
embryo	20%
rate per	15%
Birth	10%
	5%
	0%
	1991	1995	1999	2003	2007	2011	2015	2019

Under 35

35-37

38-39

40-42

43-44

45-50

3	Source: Human Fertilisation & Embryology Authority, 2021

Global access and affordability to IVF treatment is improving

Country	2022 IVF treatments	% of total
China	1,045	25%
Japan	511	12%
USA	387	9%
India	176	4%
Russia	149	4%
Spain	143	3%
Other countries	1,746	42%
Global	4,157	100%

4Source: Combination of public sources (NPESU, CDC, SART, CARTR, JSOG, ESHRE, HFEA, others) and internal estimations. RESOLVE: The National Infertility Association

Mission

Be the leading global partner in reproductive health, striving for better treatment outcomes for patients

Integrity

Quality

Global presence in

125

markets

Employees

~ 1,100

Sales in 2023

3,512MSEK

Innovation

Collaboration

5

Vision: Enable people to fulfill the dream of having a healthy baby

Portfolio covering every step of the IVF journey combined with best-in-class quality, service and training

IVF process

Prenatal & Postnatal

Pretreatment

6

Key IVF market dynamics - How can the Vitrolife Group bring value to the ecosystem

Growth in demand

Clinics labour and skills shortage

Consolidation of clinics

Regionalisation of standards of care Patient empowerment

Increase IVF capacity and accessibility

Automation and digitalisation

Standardisation and scalability

Diverse portfolio to address differences in standards of care

Communication and education

7

Corporate Strategy Vitrolife Group

Market	Growth	Labour and			Patient
megatrends	in demand	skills shortage	Consolidation	Regionalisation	empowerment

Our values

Integrity

Quality

Vision with a purpose

"Enable people to fulfil the dream of having a healthy baby"

Mission

"Be the leading global partner in reproductive health, striving for better treatment outcomes for patients"

Long-term growth and profit-targets - 5 years

Annual organic	EBITDA	Net debt/
revenue growth
(in local currencies)	margin	EBITDA
>10%	>33%	<3

Innovation

Collaboration

1.		2.		3.		4.		5.
Own the platform		Innovate to expand		Accelerate growth		Optimise go-to-		Drive operational
connecting products		leadership		in key markets		market model		excellence
and services

8	Ensure sustainability in everything we do

Strategic Priority 1: Own the platform connecting products and services

Lab control software is the layerconnecting products and services to a platform.

Consultations

Pregnancy

IVF cycle pathway

Live-birth

and treatments

supervision

Initial	Medication	Follicle	Oocyte	Sperm	Denudation,	Culture	Embryo	Cryo-	Embryo	Implantation,	Live-birth,
consult	monitoring	retrieval	preparation	fertilization	evaluation	preservation	transfer	pregnancy	newborn

IVF process

Platform layers

Product and service fulfillment

Patient journey

Clinic Management

Treatment process

Lab control

Equipment

Consumables

Gametes

Infrastructure

Software

Hardware

 Data integration with EMR 

People	Consumables	Equipment	Genetic services	Scheduling
Who did what, when?	Which consumables were	What equipment was used?	What is test status?	Are we on time?
	used?
	Did it perform to
How did it go?	Type, lot and storage history		Workflow optimisation
specification?	Biopsy and sample tracking
Training and qualification
Inventory management	What was the result?

Ensure correct match	Test reports
Maintenance and calibration
	Monitoring and alarming
	End2End Gamete tracking
	 Integration with all equipment 
eWitness	Future joint development
Functionality

KPIs	Data
How are we performing?	Is all information available?
Quality and process
performance	Connected data repository
Live tracking	Cloud enabled access from
Troubleshooting	anywhere

eWitness

Core solution

Vitrolife platfom

eFertility

9

Why Witness?

Mistakes in clinics occur

Mistakes that can happen:

Wrong embryos created/transferred

Wrong gametes thawed/destroyed Mix-up of sperm

IVF mother: 'I love him to bits. But he's probably

not mine'

Some women fear they were implanted with somebody else's baby after IVF lab errors.

The benefits

Dutch IVF centre probes suspected sperm mix-up

High efficiency during day-to-day practice

Reduced workload

Quality assurance

Outstanding reliability through error reduction

Closed loop registration through the use of one system

A Dutch IVF treatment centre has said that 26 women may have been fertilised by sperm from the wrong man.

Couple gave birth to babies of different race because of IVF mix-up

The mother, who is Asian, gave birth to two non-Asian babies, and each child was a genetic match to a different couple at CHA Fertility.